Martin Wermke

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Medicine, Genetics, Hematology +14

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke et al. · Leukemia · 2011 · 395 citations · Full text

Medicine, Hematology, Pharmacology +17

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 352 citations · Full text

Medicine, Hematology, Oncology +16

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster et al. · Blood · 2020 · 322 citations · Full text

Medicine, Hematology, Oncology +13

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Jason Chesney, Karl D. Lewis, Harriet M. Kluger et al. · Journal for ImmunoTherapy of Cancer · 2022 · 320 citations · Full text

Life Sciences, Immunology, Oncology +17